Mymetics outlines malaria vaccine approval timeline

Switzerland's Mymetics says that its experimental malaria vaccine could be ready for marketing as early as 2014. CEO Christain Rochet says that clinical trials on the vaccine--obtained from Pevion--have been carried out in Britain and Switzerland as well as developing nations. It should take another three years to complete clinical work on the vaccine, says Rochet, leading the company to conclude that marketing approval could come in six years.

"There is a pressing need for a vaccine against malaria," said the CEO. "Up to 500 million people a year are infected, with a mortality rate of approximately two million each year."

- read the AFP report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.